Inhibrx Biosciences Inc. (INBX)
INBX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$87.08
-3.81% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$1.3M
+550.0% on 2024
Net income · 2025
-$140.1M
-10773.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | INBX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002007919 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.3M |
| Net income | -$140.1M |
| Operating income | -$135.0M |
| Net margin | -10773.5% |
| Operating margin | -10386.5% |
| Revenue growth | +550.0% |
| Cash | $124.2M |
| Total assets | $146.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 985.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-06-02 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 156 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.0% |
| 1 month | -19.6% |
| 3 months | -4.6% |
| Year to date | +7.5% |
| 1 year | +147.0% |
| From 52-week high | -40.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings Inc. | $29.80 | -1.94% | $1.4B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| MAZE | Maze Therapeutics Inc. | $26.66 | -3.75% | $1.5B |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
| MGTX | MeiraGTx Holdings plc | $9.94 | -4.24% | $954.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier